Mezzion Pharma Co., Ltd. (140410)

Overview

Mezzion Pharma Co., Ltd., originally known as Dong-A Pharmtech Co., Ltd., is a biopharmaceutical company focused on the development, licensing, and commercialization of therapeutic drugs aimed at treating vascular diseases. The company embarked on its journey in 2002 and underwent a name change to Mezzion Pharma Co., Ltd. in April 2013. Based in Seoul, South Korea, Mezzion Pharma has dedicated its efforts to advancing pharmaceutical science in various therapeutic areas, harnessing its expertise to bring innovative treatments to patients worldwide.

Products and Services

• Udenafil

This flagship product of Mezzion Pharma is a PDE5 inhibitor designed to treat multiple conditions, showcasing the company’s commitment to addressing unmet medical needs across a spectrum of diseases.:

• Erectile Dysfunction: Udenafil's primary application, providing relief to patients suffering from this condition.
• Benign Prostatic Hyperplasia: It also targets this common prostate gland enlargement, offering a therapeutic solution to improve urinary symptoms.
• Pulmonary Arterial Hypertension: Utilizing its vasodilatory effects, Udenafil serves as a treatment option for this serious heart and lung condition.
• Overactive Bladder: The drug is being explored for its potential to alleviate symptoms associated with this urinary tract condition.
• Hepatic Portal Hypertension: Udenafil is under investigation for its ability to manage this elevated blood pressure within the portal vein system, a complication of liver cirrhosis.
• Chronic Obstructive Pulmonary Diseases: Its application extends to treating various respiratory disorders, emphasizing Mezzion Pharma’s dedication to respiratory health.